SLC5A2 and angina pectoris: Conflicting evidence was provided by another, more recent meta-analysis of 21 RCTs in a total of 56,064 patients with or without type 2 DM, which demonstrated a non-significant effect of SGLT-2 inhibitor treatment on the risk for AMI, unstable angina, or angina pectoris [32].